China heart drug sold globally may have had impurity since 2012

By Ben HirschlerLONDON (Reuters) - A common blood pressure and heart drug manufactured in bulk by a Chinese company and sold worldwide may have contained an impurity linked to cancer since 2012, European regulators said on Tuesday.

The revelation that the problem likely dates back to changes in manufacturing processes at Zhejiang Huahai Pharmaceutical six years ago suggests many patients could potentially have been exposed to cancer risk.The European Medicines Agency (EMA), which first raised the alarm over the Chinese supplied valsartan on July.....

This article is no longer available in our repository.

There could be multiple reasons for this.